Literature DB >> 9351022

Effects of riluzole on the evolution of focal cerebral ischemia: a magnetic resonance imaging study.

I Mottet1, R Demeure, J Rataud, M Lucas, F Wahl, V Warscotte, J P Thiran, J F Goudemant, B Maldague, J M Maloteaux, J M Stutzmann.   

Abstract

The aim of this study was to investigate the effects of riluzole on the lesion induced by a permanent middle cerebral artery occlusion (MCAO) in rats. Riluzole at 4 or 8 mg/kg i.v. significantly reduced the cortical ischemic brain damage. With the most effective dose of 8 mg/kg, the time evolution of the lesion was assessed by T2-weighted magnetic resonance imaging (MRI) repeated on the same animals after MCAO. MRI obtained at 24, 48, and 72 hours after MCAO showed a progressive increase of the ischemic lesion, except in the cortex of the riluzole-treated rats (8 mg/kg i.v.). Furthermore, there was no difference between lesion volumes as measured by MRI or by histology. This study indicates that MRI may be a valuable method to quantify in vivo the neuroprotective profile of a drug.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351022     DOI: 10.1007/bf02594581

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  26 in total

1.  Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells.

Authors:  A Doble; J P Hubert; J C Blanchard
Journal:  Neurosci Lett       Date:  1992-06-22       Impact factor: 3.046

2.  Image analysis using mathematical morphology.

Authors:  R M Haralick; S R Sternberg; X Zhuang
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1987-04       Impact factor: 6.226

3.  Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre.

Authors:  E Benoit; D Escande
Journal:  Pflugers Arch       Date:  1991-12       Impact factor: 3.657

4.  Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils.

Authors:  C Malgouris; F Bardot; M Daniel; F Pellis; J Rataud; A Uzan; J C Blanchard; P M Laduron
Journal:  J Neurosci       Date:  1989-11       Impact factor: 6.167

Review 5.  Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology.

Authors:  B K Siesjö
Journal:  J Neurosurg       Date:  1992-08       Impact factor: 5.115

6.  The dose-response relationship and therapeutic window for dizocilpine (MK-801) in a rat focal ischaemia model.

Authors:  R H Hatfield; R Gill; C Brazell
Journal:  Eur J Pharmacol       Date:  1992-05-27       Impact factor: 4.432

7.  Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents.

Authors:  J Rataud; F Debarnot; V Mary; J Pratt; J M Stutzmann
Journal:  Neurosci Lett       Date:  1994-05-19       Impact factor: 3.046

8.  Magnetic resonance imaging and 31P magnetic resonance spectroscopy for evaluating focal cerebral ischemia.

Authors:  I M Germano; L H Pitts; I Berry; M Moseley
Journal:  J Neurosurg       Date:  1989-04       Impact factor: 5.115

9.  Application of magnetic resonance imaging to the measurement of neurodegeneration in rat brain: MRI data correlate strongly with histology and enzymatic analysis.

Authors:  P R Allegrini; D Sauer
Journal:  Magn Reson Imaging       Date:  1992       Impact factor: 2.546

10.  Diffusion- and T2-weighted imaging: evaluation of oedema reduction in focal cerebral ischaemia by the calcium and serotonin antagonist levemopamil.

Authors:  J Seega; B Elger
Journal:  Magn Reson Imaging       Date:  1993       Impact factor: 2.546

View more
  2 in total

Review 1.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

2.  Early identification of potentially salvageable tissue with MRI-based predictive algorithms after experimental ischemic stroke.

Authors:  Mark J R J Bouts; Ivo A C W Tiebosch; Annette van der Toorn; Max A Viergever; Ona Wu; Rick M Dijkhuizen
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-10       Impact factor: 6.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.